Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumour-directed immuno-oncology antibody drugs, announced on Friday that it has named Dr Malin Carlsson as its new chief operating officer, effective 1 January 2020.
Dr Carlsson most recently held the position of vice president, head of Translational Medicine at Ferring Pharmaceuticals in Copenhagen. She is a medical doctor with specialist qualifications and a PhD in clinical immunology. She also has many years of industrial experience from various senior roles in major international pharmaceutical companies such as AstraZeneca, Nycomed, Takeda and Ferring.
Per Norlén, Alligator Bioscience CEO, said, 'I am very pleased with the successful recruitment of Malin Carlsson to Alligator. Her international experience in leading clinical development and in building development organisations will significantly strengthen our clinical capacity. This is crucial in the phase we are in now, with two products on the way to phase II and another product in clinical phase I. We look forward to welcoming Malin to Lund and to our management team.'
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business